MEK is a key protein kinase in the RAS/RAF/MEK/ERK pathway, which signals cancer cell proliferation and survival. MEK has been shown to be frequently activated in cancer, in particular in tumors that have mutations in the RAS and RAF pathways.
As per the agreement, Array is expected to receive $45m initially, which include an upfront and milestone payment and is eligible to receive an additional $422m if certain clinical, regulatory and commercial milestones are achieved.
In addition, Array plans to co-develop ARRY-162 in one or more specific indications and fund a portion of development costs.
Array BioPharma said that the agreement provides it with double-digit royalties on sales of approved drugs outside of the US, with a higher royalty rate for US sales provided that Array meets its co-funding obligations. Array also has a co-detailing right in the US for approved drugs.
Robert Conway, CEO of Array BioPharma, said: “This agreement with Novartis is a major advance in our strategic objective to become a fully integrated, commercial-stage biopharmaceutical company. We believe ARRY-162 will benefit from the additional resources of a major pharmaceutical company to rapidly maximise its promise as a cancer treatment, both as a single agent and in combination therapy. Novartis is the right partner because of its track record in developing and commercialising important new cancer therapies.”